Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04601909 · ClinicalTrials.gov registry record · Phase 1
FX-322 in Adults With Age-Related Sensorineural Hearing Loss
A Phase 1 study, sponsored by Frequency Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT04601909 is a Phase 1 study that has completed, run by Frequency Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT04601909, a Phase 1 study, has completed, sponsored by Frequency Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase 1b, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter, safety study of FX-322, administered by intratympanic injection, in adults with age-related sensorineural hearing loss.
Interventions
- OTHER placebo
- DRUG FX-322
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-09-17 |
| Est. Completion | 2022-05-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04601909
The ClinicalTrials.gov registry entry for NCT04601909 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Frequency Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT04601909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04601909 about?
NCT04601909 is a clinical study titled "FX-322 in Adults With Age-Related Sensorineural Hearing Loss". This is a Phase 1b, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter, safety study of FX-322, administered by intratympanic injection, in adults with age-related sensorineural hearing loss.
What is the current status of trial NCT04601909?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2020-09-17. Estimated completion is 2022-05-16.
What interventions are being tested in trial NCT04601909?
The interventions under investigation include: placebo (OTHER), FX-322 (DRUG).
Who is sponsoring clinical trial NCT04601909?
This trial is sponsored by Frequency Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.